Companies › Sagimet Biosciences
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Immunology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Denifanstat DGAT2 inhibitor | DGAT2 | Phase 3 | Acne Vulgaris | Aug 2027 |
| TVB-3567 | – | Phase 1 | Acne | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06989840 | TVB-3567 | Phase 1 | Acne | Immunology | Jan 2027 |
| NCT07863193 | Denifanstat | Phase 3 | Acne Vulgaris | Immunology | Aug 2027 |
Cash and short-term investments of $258m on 2026-06-30; operating cash outflow about $40m a year; runway about 77 months at that burn, to Dec 2032; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 10 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
BioCryst Pharmaceuticals Hangzhou Highlightll Pharmaceutical Veradermics Palisade Bio Prime Gene Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.